The 503B Loophole Closes: Why the FDA is Moving to Exclude GLP-1s from Bulk Compounding

On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As legitimate compounding pathways narrow, independent analytical testing becomes the only reliable defense against substandard supply.
The Invisible Foundation: Why Your BAC Water Matters More Than You Think

When a peptide seems to fail, the bacteriostatic water is often the cause. Why the water you reconstitute with deserves testing too.
The Amazon Peptide Problem: Why Third-Party Testing Matters More Than Ever

A 2025 AP investigation found research peptides sold on Amazon, Walmart and Alibaba with little oversight. What it found and why third-party testing matters.
What Happens Inside Your Body When Purity Fails

A 98 or 99 percent purity number says nothing about what makes up the rest. What impurities can do in the body when purity falls short.